Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

HPV helps drive flu vaccine revenues to $16.3 bn

Kalorama Information : 08 April, 2008  (Company News)
Stronger than anticipated revenues for flu vaccines together with the commercial success of Merck’s Gardasil for HPV, which causes most cervical cancers, has seen vaccine sales in 2007 rise to $16.3 billion.
The figure represents an increase of 38 percent compared with 2006 sales of $11.7 billion, according to ‘Vaccines 2008: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry’, a new market research study and reforecast of the vaccine market from Kalorama Information.

According to the report, new products approved in recent years, in particular Gardasil, but also RotaTeq, Pentacel, Zostavax and FluMist, are now having an impact on the market. These new products, combined with a continued emphasis on flu vaccines in the US healthcare system, have created a healthy environment for vaccine products.

Five major players – Merck, GlaxoSmithKline, Sanofi Pasteur, Wyeth and Novartis – dominate vaccine sales. At these companies, as well as smaller producers, Kalorama Information has found increased interest in vaccines, and a willingness to look at products for conditions not historically addressed with vaccines, including diabetes, cancer and smoking cessation. Given this trend and strong sales, Kalorama Information expects vaccine sales to more than double in five years.

“You might call it a ‘Gardasil Effect’,” explained Bruce Carlson, publisher of Kalorama Information. “R and D departments are more confident about investing in a vaccine product now than in the past because a strong marketing precedent has been established. Expect to see new vaccine products, and perhaps new companies in the market.”

Kalorama Information’s new report ‘Vaccines 2008: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry’ reforecasts the market for the highly profitable drug segment and addresses the changes taking place. The report covers current world revenues and forecasts through 2013 for paediatric and adult vaccines, and provides pipeline analysis and company profiles.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   Â© 2012
Netgains Logo